OncLive TV

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.

Rebecca Klisovic, MD, discusses updates with JAK inhibitors, highlighting factors that inform JAK inhibitor selection in myelofibrosis.

Axel Hauschild, MD, PhD, discusses research with adjuvant immunotherapy in CSCC and immunotherapy indications in basal cell carcinoma.

David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.

Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.

Josep Maria Piulats Rodriguez, MD, PhD, discusses the rationale for identifying predictive biomarkers for talazoparib plus enzalutamide in mCRPC.

Guenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.

Hua-Jay "Jeff" Cherng on approvals of epcoritamab and glofitamab for relapsed/refractory DLBCL

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Michael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.